https://stock.noler.com/us/stock/correvio-pharma-corp https://stock.noler.com/us/stock/correvio-pharma-corp/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/correvio-pharma-corp/accounts-payable-related-parties-current https://stock.noler.com/us/stock/correvio-pharma-corp/accounts-payable-trade-current-and-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/accretion-expense https://stock.noler.com/us/stock/correvio-pharma-corp/accumulated-depreciation https://stock.noler.com/us/stock/correvio-pharma-corp/accumulated-oci-foreign-currency-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-current-assets-prepaid-expense-and-other-assets https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-current-assets-receivables https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-current-liabilities-accounts-payable https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-intangibles https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-inventory https://stock.noler.com/us/stock/correvio-pharma-corp/acquired-property-plant-and-equipment https://stock.noler.com/us/stock/correvio-pharma-corp/acquisition-acquired-receivables-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/acquisition-acquisition-related-costs https://stock.noler.com/us/stock/correvio-pharma-corp/acquisition-consideration-transferred https://stock.noler.com/us/stock/correvio-pharma-corp/acquisition-consideration-transferred-equity-interests-issued-and-issuable https://stock.noler.com/us/stock/correvio-pharma-corp/acquisition-recognized-identifiable-assets-acquired-goodwill-and-liabilities-assumed-net https://stock.noler.com/us/stock/correvio-pharma-corp/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/correvio-pharma-corp/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/correvio-pharma-corp/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/correvio-pharma-corp/adjustment-for-amortization https://stock.noler.com/us/stock/correvio-pharma-corp/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/correvio-pharma-corp/amended-reports-20-f https://stock.noler.com/us/stock/correvio-pharma-corp/amended-reports-40-f https://stock.noler.com/us/stock/correvio-pharma-corp/amortization https://stock.noler.com/us/stock/correvio-pharma-corp/amortization-of-financing-costs https://stock.noler.com/us/stock/correvio-pharma-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/correvio-pharma-corp/basic-shares https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisition-equity-interests-issued-or-issuable-number-of-shares-issued https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisition-pro-forma-earnings-per-share-basic https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisition-pro-forma-earnings-per-share-diluted https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisitions-pro-forma-income-loss-from-before-changes-in-accounting-and-extraordinary-items-net-of-tax https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisitions-pro-forma-net-income-loss https://stock.noler.com/us/stock/correvio-pharma-corp/business-acquisitions-pro-forma-revenue https://stock.noler.com/us/stock/correvio-pharma-corp/capital-expenditures https://stock.noler.com/us/stock/correvio-pharma-corp/cash-acquired-from-acquisition https://stock.noler.com/us/stock/correvio-pharma-corp/cash-and-equivalents https://stock.noler.com/us/stock/correvio-pharma-corp/cash-and-restricted-cash https://stock.noler.com/us/stock/correvio-pharma-corp/cash-and-restricted-cash-change-excluding-exchange-rate-effect https://stock.noler.com/us/stock/correvio-pharma-corp/cash-flow-breakdown https://stock.noler.com/us/stock/correvio-pharma-corp/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/correvio-pharma-corp/common-stock-no-par-value https://stock.noler.com/us/stock/correvio-pharma-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/correvio-pharma-corp/common-stock-value https://stock.noler.com/us/stock/correvio-pharma-corp/comprehensive-income https://stock.noler.com/us/stock/correvio-pharma-corp/concentration-risk-percentage https://stock.noler.com/us/stock/correvio-pharma-corp/cost-of-goods-sold https://stock.noler.com/us/stock/correvio-pharma-corp/cost-of-revenue https://stock.noler.com/us/stock/correvio-pharma-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/correvio-pharma-corp/cumulative-effect-of-new-accounting-principle-in-period-of-adoption https://stock.noler.com/us/stock/correvio-pharma-corp/current-assets https://stock.noler.com/us/stock/correvio-pharma-corp/current-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/current-portion-of-long-term-debt https://stock.noler.com/us/stock/correvio-pharma-corp/debt-carrying-amount https://stock.noler.com/us/stock/correvio-pharma-corp/debt-face-amount https://stock.noler.com/us/stock/correvio-pharma-corp/debt-interest-rate-effective-percentage https://stock.noler.com/us/stock/correvio-pharma-corp/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/correvio-pharma-corp/debt-issued https://stock.noler.com/us/stock/correvio-pharma-corp/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/correvio-pharma-corp/debt-maturing-in-year-five https://stock.noler.com/us/stock/correvio-pharma-corp/debt-maturing-in-year-four https://stock.noler.com/us/stock/correvio-pharma-corp/debt-maturing-in-year-three https://stock.noler.com/us/stock/correvio-pharma-corp/debt-maturing-in-year-two https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-income-tax-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-rent-credit-current https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-revenue https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-revenue-change https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-revenue-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-gross https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-liabilities-net-current https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-other https://stock.noler.com/us/stock/correvio-pharma-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/correvio-pharma-corp/depreciation https://stock.noler.com/us/stock/correvio-pharma-corp/depreciation-and-amortization https://stock.noler.com/us/stock/correvio-pharma-corp/depreciation-and-amortization-expense https://stock.noler.com/us/stock/correvio-pharma-corp/diluted-shares https://stock.noler.com/us/stock/correvio-pharma-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/correvio-pharma-corp/effect-of-exchange-rate-on-cash-and-restricted-cash https://stock.noler.com/us/stock/correvio-pharma-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/correvio-pharma-corp/entity-wide-revenue-major-customer-percentage https://stock.noler.com/us/stock/correvio-pharma-corp/eps https://stock.noler.com/us/stock/correvio-pharma-corp/eps-basic https://stock.noler.com/us/stock/correvio-pharma-corp/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/correvio-pharma-corp/federal-income-tax-expense-benefit https://stock.noler.com/us/stock/correvio-pharma-corp/financing-cash-flow https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/correvio-pharma-corp/finite-lived-trade-names-gross https://stock.noler.com/us/stock/correvio-pharma-corp/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/correvio-pharma-corp/foreign-currency-transaction-gain-loss-realized https://stock.noler.com/us/stock/correvio-pharma-corp/foreign-currency-transaction-gain-loss-unrealized https://stock.noler.com/us/stock/correvio-pharma-corp/gain-loss-on-sale-of-business https://stock.noler.com/us/stock/correvio-pharma-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/correvio-pharma-corp/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/correvio-pharma-corp/general-and-administrative-expense https://stock.noler.com/us/stock/correvio-pharma-corp/goodwill https://stock.noler.com/us/stock/correvio-pharma-corp/gross-profit https://stock.noler.com/us/stock/correvio-pharma-corp/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/correvio-pharma-corp/impairment-of-long-lived-assets-to-be-disposed-of https://stock.noler.com/us/stock/correvio-pharma-corp/incentive-from-lessor https://stock.noler.com/us/stock/correvio-pharma-corp/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/correvio-pharma-corp/income-tax https://stock.noler.com/us/stock/correvio-pharma-corp/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/correvio-pharma-corp/income-taxes-paid https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-receivables https://stock.noler.com/us/stock/correvio-pharma-corp/increase-decrease-in-restricted-cash-for-operating-activities https://stock.noler.com/us/stock/correvio-pharma-corp/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/correvio-pharma-corp/interest-expense https://stock.noler.com/us/stock/correvio-pharma-corp/interest-expense-on-debt https://stock.noler.com/us/stock/correvio-pharma-corp/interest-income-deposits-with-financial-institutions https://stock.noler.com/us/stock/correvio-pharma-corp/interest-income-foreign-deposits https://stock.noler.com/us/stock/correvio-pharma-corp/interest-paid https://stock.noler.com/us/stock/correvio-pharma-corp/interest-paid-net https://stock.noler.com/us/stock/correvio-pharma-corp/interest-payable-current-and-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/inventory https://stock.noler.com/us/stock/correvio-pharma-corp/inventory-finished-goods https://stock.noler.com/us/stock/correvio-pharma-corp/inventory-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/inventory-raw-materials https://stock.noler.com/us/stock/correvio-pharma-corp/inventory-work-in-process https://stock.noler.com/us/stock/correvio-pharma-corp/inventory-write-down https://stock.noler.com/us/stock/correvio-pharma-corp/investing-cash-flow https://stock.noler.com/us/stock/correvio-pharma-corp/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/correvio-pharma-corp/license-and-services-revenue https://stock.noler.com/us/stock/correvio-pharma-corp/line-of-credit-facility-increase-additional-borrowings https://stock.noler.com/us/stock/correvio-pharma-corp/long-term-debt https://stock.noler.com/us/stock/correvio-pharma-corp/long-term-debt-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/net-change-in-cash https://stock.noler.com/us/stock/correvio-pharma-corp/net-income https://stock.noler.com/us/stock/correvio-pharma-corp/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/correvio-pharma-corp/new-accounting-pronouncement-or-change-in-accounting-principle-cumulative-effect-of-change-on-equity-or-net-assets https://stock.noler.com/us/stock/correvio-pharma-corp/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/correvio-pharma-corp/operating-cash-flow https://stock.noler.com/us/stock/correvio-pharma-corp/operating-expenses https://stock.noler.com/us/stock/correvio-pharma-corp/operating-income https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-assets https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-cost https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-liability https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-liability-current https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-2 https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/correvio-pharma-corp/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/correvio-pharma-corp/operating-leases-rent-expense-net https://stock.noler.com/us/stock/correvio-pharma-corp/operating-leases-rent-expense-sublease-rentals https://stock.noler.com/us/stock/correvio-pharma-corp/operating-loss-carryforwards https://stock.noler.com/us/stock/correvio-pharma-corp/other-accrued-liabilities-current https://stock.noler.com/us/stock/correvio-pharma-corp/other-income https://stock.noler.com/us/stock/correvio-pharma-corp/other-inventory-materials-supplies-and-merchandise-under-consignment https://stock.noler.com/us/stock/correvio-pharma-corp/other-noncash-income https://stock.noler.com/us/stock/correvio-pharma-corp/other-noncurrent-assets https://stock.noler.com/us/stock/correvio-pharma-corp/other-noncurrent-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/other-nonoperating-expense https://stock.noler.com/us/stock/correvio-pharma-corp/other-nonoperating-income https://stock.noler.com/us/stock/correvio-pharma-corp/other-nonoperating-income-expense https://stock.noler.com/us/stock/correvio-pharma-corp/paid-in-capital-share-based-compensation-and-exercise-of-stock-options https://stock.noler.com/us/stock/correvio-pharma-corp/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/correvio-pharma-corp/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/correvio-pharma-corp/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/correvio-pharma-corp/paid-in-kind-interest https://stock.noler.com/us/stock/correvio-pharma-corp/payments-for-restructuring https://stock.noler.com/us/stock/correvio-pharma-corp/payments-of-debt-extinguishment-costs https://stock.noler.com/us/stock/correvio-pharma-corp/payments-of-financing-costs https://stock.noler.com/us/stock/correvio-pharma-corp/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/correvio-pharma-corp/payments-to-acquire-businesses-gross https://stock.noler.com/us/stock/correvio-pharma-corp/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/correvio-pharma-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/correvio-pharma-corp/pretax-income https://stock.noler.com/us/stock/correvio-pharma-corp/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/correvio-pharma-corp/proceeds-from-issuance-of-secured-debt https://stock.noler.com/us/stock/correvio-pharma-corp/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/correvio-pharma-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/correvio-pharma-corp/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/correvio-pharma-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/correvio-pharma-corp/property-plant-equipment https://stock.noler.com/us/stock/correvio-pharma-corp/purchase-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/correvio-pharma-corp/purchase-obligation-due-in-second-year https://stock.noler.com/us/stock/correvio-pharma-corp/purchase-obligation-due-in-third-year https://stock.noler.com/us/stock/correvio-pharma-corp/receivables-net-current https://stock.noler.com/us/stock/correvio-pharma-corp/recorded-unconditional-purchase-obligation-due-in-third-year https://stock.noler.com/us/stock/correvio-pharma-corp/related-party-transaction-selling-general-and-administrative-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/correvio-pharma-corp/repayments-of-secured-debt https://stock.noler.com/us/stock/correvio-pharma-corp/research-and-development-arrangement-contract-to-perform-for-others-compensation-earned https://stock.noler.com/us/stock/correvio-pharma-corp/research-and-development-expense-excluding-acquired-in-process-cost https://stock.noler.com/us/stock/correvio-pharma-corp/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/correvio-pharma-corp/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-charges https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-reserve https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-reserve-accrual-adjustment https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-reserve-settled-with-cash https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-reserve-settled-without-cash https://stock.noler.com/us/stock/correvio-pharma-corp/restructuring-reserve-settled-without-cash-1 https://stock.noler.com/us/stock/correvio-pharma-corp/retained-earnings https://stock.noler.com/us/stock/correvio-pharma-corp/revenue https://stock.noler.com/us/stock/correvio-pharma-corp/revenue-from-contract-with-customer-including-assessed-tax https://stock.noler.com/us/stock/correvio-pharma-corp/revenue-recognition-milestone-method-revenue-recognized https://stock.noler.com/us/stock/correvio-pharma-corp/sales-revenue-goods-net https://stock.noler.com/us/stock/correvio-pharma-corp/sec-comment-letters-corresp https://stock.noler.com/us/stock/correvio-pharma-corp/sec-comment-letters-upload https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-15-12g https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-20-f https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-25-nse https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-40-f https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-6-k https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-8-k12g3 https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-ct-order https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-f-10pos https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-f-x https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-regdex https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-sc-to-c https://stock.noler.com/us/stock/correvio-pharma-corp/sec-filings-suppl https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-effect https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-f-10 https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-f-3 https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-fwp https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/correvio-pharma-corp/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/correvio-pharma-corp/secured-debt-current https://stock.noler.com/us/stock/correvio-pharma-corp/secured-long-term-debt https://stock.noler.com/us/stock/correvio-pharma-corp/sga-expense https://stock.noler.com/us/stock/correvio-pharma-corp/share-price https://stock.noler.com/us/stock/correvio-pharma-corp/shareholders-equity https://stock.noler.com/us/stock/correvio-pharma-corp/shares-issued https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-compensation-cost https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-aggregate-intrinsic-value-nonvested https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-aggregate-intrinsic-value-vested https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-forfeited-in-period https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-forfeitures-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-grants-in-period https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-vested-in-period https://stock.noler.com/us/stock/correvio-pharma-corp/stock-award-rsu-vested-in-period-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-based-compensation https://stock.noler.com/us/stock/correvio-pharma-corp/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/correvio-pharma-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/correvio-pharma-corp/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/correvio-pharma-corp/stock-issued-shares-issued-shares-new-issues https://stock.noler.com/us/stock/correvio-pharma-corp/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/correvio-pharma-corp/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/correvio-pharma-corp/stock-option-plan-expense https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-expirations-in-period https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-nonvested-number-of-shares https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-nonvested-options-forfeited-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-nonvested-options-forfeited-number-of-shares https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-grant-date-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-in-period-fair-value-1 https://stock.noler.com/us/stock/correvio-pharma-corp/stock-options-vested-number-of-shares https://stock.noler.com/us/stock/correvio-pharma-corp/stockholders-equity-including-portion-attributable-to-noncontrolling-interest-adjusted-balance https://stock.noler.com/us/stock/correvio-pharma-corp/tangible-asset-impairment-charges https://stock.noler.com/us/stock/correvio-pharma-corp/tax-adjustments-settlements-and-unusual-provisions https://stock.noler.com/us/stock/correvio-pharma-corp/tax-credit-carryforward-amount https://stock.noler.com/us/stock/correvio-pharma-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/correvio-pharma-corp/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-disposition-of-business https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-other-reconciling-items https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-prior-year-income-taxes https://stock.noler.com/us/stock/correvio-pharma-corp/tax-reconciliation-tax-credits-investment https://stock.noler.com/us/stock/correvio-pharma-corp/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/correvio-pharma-corp/total-assets https://stock.noler.com/us/stock/correvio-pharma-corp/total-liabilities https://stock.noler.com/us/stock/correvio-pharma-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/correvio-pharma-corp/total-long-term-debt https://stock.noler.com/us/stock/correvio-pharma-corp/unamortized-debt-issuance-expense https://stock.noler.com/us/stock/correvio-pharma-corp/unrecognized-tax-benefits https://stock.noler.com/us/stock/correvio-pharma-corp/variable-lease-cost https://stock.noler.com/us/stock/correvio-pharma-corp/warrants-not-settleable-in-cash-fair-value-disclosure https://stock.noler.com/us/stock/correvio-pharma-corp/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/correvio-pharma-corp/weighted-average-rate-foreign-deposit-time-deposit https://stock.noler.com/us/stock/correvio-pharma-corp/write-off-of-deferred-debt-issuance-cost